Effect of angiotensin II receptor blocker on experimental periodontitis in a mouse model of marfan syndrome

Infection and Immunity

Volumn 81, Issue 1, 2013, Pages 182-188

  Suda, Naoto ^a   Moriyama, Keiji ^b   Ganburgedc, Ganjargal ^c  

^a MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c Health Science's University of Mongolia   (Mongolia)

Author keywords

[No Author keywords available]

Indexed keywords

CUTANEOUS T CELL ATTRACTING CHEMOKINE; EOTAXIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 2; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC PERIODONTITIS; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; HETEROZYGOTE; MALE; MARFAN SYNDROME; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOLYSIS; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL;

ALVEOLAR BONE LOSS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; BACTEROIDACEAE INFECTIONS; BENZIMIDAZOLES; BENZOATES; BONE RESORPTION; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERLEUKIN-17; MALE; MARFAN SYNDROME; MICE; OSTEOCLASTS; PERIODONTITIS; PORPHYROMONAS GINGIVALIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871890113     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00886-12     Document Type: Article

References (46)

1. Hujoel P, Zina LG, Cunha-Cruz J, Lopez R. 2012. Historical perspectives on theories of periodontal disease etiology. Periodontol. 2000. 58:153-160.
2. Fox CH. 1992. New considerations in the prevalence of periodontal disease. Curr. Opin. Dent. 2:5-11.
3. Fox CH, Jette AM, McGuire SM, Feldman HA, Douglass CW. 1994. Periodontal disease among New England elders. J. Periodontol. 65:676-684.
4. O'Dowd LK, Durham J, McCracken GI, Preshaw PM. 2010. Patients' experiences of the impact of periodontal disease. J. Clin. Periodontol. 37:334-339.
5. Pihlstrom BL. 2001. Periodontal risk assessment, diagnosis and treatment planning. Periodontol. 2000 25:37-58.
6. Christersson LA, Zambon JJ, Genco RJ. 1991. Dental bacterial plaques. Nature and role in periodontal disease. J. Clin. Periodontol. 18:441-446.
7. Dietz HC. 1991. Marfan syndrome caused by a recurrent de novo mis-sense mutation in the fibrillin gene. Nature 352:337-339.
8. McKusick VA. 1991. The defect in Marfan syndrome. Nature 352:279-281.
9. Judge DP, Dietz HC. 2005. Marfan's syndrome. Lancet 366:1965-1976.
10. Ramirez F, Dietz HC. 2009. Extracellular microfibrils in vertebrate development and disease processes. J. Biol. Chem. 284:14677-14681.
11. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC. 2006. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:117-121.
12. Brooke BS. 2008. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N. Engl. J. Med. 358:2787-2795.
13. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. 2003. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat. Genet. 33:407-411.
14. Shiga M, Saito M, Hattori M, Torii C, Kosaki K, Kiyono T, Suda N. 2008. Characteristic phenotype of immortalized periodontal cells isolated from a Marfan syndrome type I patient. Cell Tissue Res. 331:461-472.
15. Straub AM, Grahame R, Scully C, Tonetti MS. 2002. Severe periodontitis in Marfan's syndrome: a case report. J. Periodontol. 73:823-826.
16. De Coster PJ, Martens LC, De Paepe A. 2002. Oral manifestations of patients with Marfan syndrome: a case-control study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 93:564-572.
17. Takagi H, Yamamoto H, Iwata K, Goto SN, Umemoto T. 2012. An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome. Int. J. Cardiol. 158:101-102.
18. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. 2004. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993-1002.
19. Kaschina E, Schrader F, Sommerfeld M, Kemnitz UR, Grzesiak A, Krikov M, Unger T. 2008. Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J. Hypertens. 26:2361-2373.
20. Ohno K, Amano Y, Kakuta H, Niimi T, Takakura S, Orita M, Miyata K, Sakashita H, Takeuchi M, Komuro I, Higaki J, Horiuchi M, Kim-Mitsuyama S, Mori Y, Morishita R, Yamagishi S. 2011. Unique "delta lock" structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor. Biochem. Biophys. Res. Commun. 404: 434-437.
21. Pereira L, Andrikopoulos K, Tian J, Lee SY, Keene DR, Ono R, Reinhardt DP, Sakai LY, Biery NJ, Bunton T, Dietz HC, Ramirez F. 1997. Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat. Genet. 17:218-222.
22. Houri-Haddad Y, Soskolne WA, Halabi A, Barak V, Shapira L. 2000. Repeat bacterial challenge in a subcutaneous chamber model results in augmented tumour necrosis factor-alpha and interferon-gamma response, and suppression of interleukin-10. Immunology 99:215-220.
23. Baker PJ, Dixon M, Roopenian DC. 2000. Genetic control of susceptibility to Porphyromonas gingivalis-induced alveolar bone loss in mice. Infect. Immun. 68:5864-5868.
24. Lalla E, Lamster IB, Hofmann MA, Bucciarelli L, Jerud AP, Tucker S, Lu Y, Papapanou PN, Schmidt AM. 2003. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 23:1405-1411.
25. Koshizaka M, Takemoto M, Sato S, Tokuyama H, Fujimoto M, Okabe E, Ishibashi R, Ishikawa T, Tsurutani Y, Onishi S, Mezawa M, He P, Honjo S, Ueda S, Saito Y, Yokote K. 2012. An angiotensin II type 1 receptor blocker prevents renal injury via inhibition of the Notch pathway in Ins2 Akita diabetic mice. Exp. Diabetes Res. 2012:159874. doi:10.1155 /2012/159874.
26. Toyama K, Nakamura T, Kataoka K, Yasuda O, Fukuda M, Tokutomi Y, Dong YF, Ogawa H, Kim-Mitsuyama S. 2011. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity. Biochem. Biophys. Res. Commun. 410:508-513.
27. Li CH, Amar S. 2007. Morphometric, histomorphometric, and microcomputed tomographic analysis of periodontal inflammatory lesions in a murine model. J. Periodontol. 78:1120-1128.
28. Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. 1995. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem. Biophys. Res. Commun. 206:89-96.
29. Page RC, Schroeder HE. 1982. Periodontitis in man and other animals: a comparative review, p 5-41. Karger Medical and Scientific Publishers, Basel, Switzerland.
30. Slots J, Listgarten MA. 1988. Bacteroides gingivalis, Bacteroides intermedius and Actinobacillus actinomycetemcomitans in human periodontal diseases. J. Clin. Periodontol. 15:85-93.
31. Baker PJ, Dixon M, Evans RT, Roopenian DC. 2000. Heterogeneity of Porphyromonas gingivalis strains in the induction of alveolar bone loss in mice. Oral Microbiol. Immunol. 15:27-32.
32. Madden TE, Caton JG. 1994. Animal models for periodontal disease. Methods Enzymol. 235:106-119.
33. Page RC, Schroeder HE. 1982. Periodontitis in man and other animals: a comparative review, p 222-283. Karger Medical and Scientific Publishers, Basel, Switzerland.
34. Weinberg MA, Bral M. 1999. Laboratory animal models in periodontology. J. Clin. Periodontol. 26:335-340.
35. Wilensky A, Gabet Y, Yumoto H, Houri-Haddad Y, Shapira L. 2005. Three-dimensional quantification of alveolar bone loss in Porphyromonas gingivalis-infected mice using micro-computed tomography. J. Periodontol. 76:1282-1286.
36. Genco CA, Van Dyk T, Amar S. 1998. Animal models for Porphyromonas gingivalis-mediated periodontal disease. Trends Microbiol. 6:444-449.
37. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, Boots AM, Gram H, Joosten LA, van den Berg WB. 2005. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am. J. Pathol. 167:141-149.
38. Mayer Y, Balbir-Gurman A, Machtei EE. 2009. Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis. J. Periodontol. 80:1414-1420.
39. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T. 2000. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-286.
40. Yago T, Nanke Y, Ichikawa N, Kobashigawa T, Mogi M, Kamatani N, Kotake S. 2009. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J. Cell Biochem. 108:947-955.
41. Karlberg BE, Lins LE, Hermansson K. 1999. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J. Hypertens. 17:293-302.
42. Habashi JP, Doyle JJ, Holm TM, Aziz H, Schoenhoff F, Bedja D, Chen Y, Modiri AN, Judge DP, Dietz HC. 2011. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 332:361-365.
43. Takahashi T, Ono H, Ono Y, Ishimitsu T, Matsuoka H. 2007. Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta. Int. Heart J. 48:637-647.
44. Hart GT, Shaffer DJ, Akilesh S, Brown AC, Moran L, Roopenian DC, Baker PJ. 2004. Quantitative gene expression profiling implicates genes for susceptibility and resistance to alveolar bone loss. Infect. Immun. 72: 4471-4479.
45. Behfarnia P, Birang R, Andalib AR, Asadi S. 2010. Comparative evaluation of IFNγ, IL4 and IL17 cytokines in healthy gingiva and moderate to advanced chronic periodontitis. Dent. Res. J. (Isfahan) 7:45-50.
46. Ohshima M, Yamaguchi Y, Matsumoto N, Micke P, Takenouchi Y, Nishida T, Kato M, Komiyama K, Abiko Y, Ito K, Otsuka K, Kap K. 2010. TGF-Β signaling in gingival fibroblast-epithelial interaction. J. Dent. Res. 89:1315-1321.